BIOTRON LIMITED — Investor Presentation 2013

Jun 30, 2013

==> picture [227 x 35] intentionally omitted <==

Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au

1 July 2013

The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000

(15 pages by email)

Dear Madam

PRESENTATION OF HIV TRIAL DATA AT

INTERNATIONAL AIDS SOCIETY CONFERENCE

• Positive antiviral efficacy data in Phase 2a clinical trial presented to international audience

• Data shows BIT225 targets virus 'hiding' in reservoir precursor cells

• BIT225 treatment resulted in significantly reduced production of virus by these cells

Biotron Limited (ASX: BIT) has presented results from a human trial of its lead antiviral drug BIT225 at the 7th International AIDS Society (IAS) conference, being held in Kuala Lumpur, Malaysia this week. It is the world’s largest open scientific conference on HIV and AIDS.

In addition, Biotron presented data from the trial at the satellite 'Towards an HIV Cure' symposium, which was held in the 2 days immediately prior to IAS 2013.

In late 2012, Biotron completed the clinical phase of a Phase 1b/2a trial of BIT225 in HIV-1 infected individuals. The trial, which was performed at Siriraj Hospital, Bangkok, Thailand, was designed to demonstrate that BIT225 is able to target and reduce virus levels in monocyte lineage cells. During HIV infection, these cells become infected with the virus and are the seeds of hidden HIV pools in patients, setting up long-lived macrophage reservoir cell populations in various sites in the body.

Data presented at the conference has demonstrated that BIT225 targets HIV replication in monocyte cells in treated patients, resulting in significant reduction in virus levels within these reservoir precursor cells.

Targeting virus within monocyte lineage cells is central to preventing the ongoing cycle of infection and re-infection of T cells with virus from these reservoirs in HIV-infected patients. This trial is the first demonstration of the feasibility of such an approach.

Virus levels in monocytes were assessed by measuring changes in the amount of virus produced by the trial participants' cells during 10 days of treatment with BIT225. To measure changes in virus, monocytes were isolated from the participants' blood during their course of treatment with either BIT225 or placebo, and cultured in the laboratory for 25 days.

Measurement of HIV in the cell cultures demonstrated that there was a reduction in virus production by monocyte cells collected during treatment with BIT225.

The most pronounced antiviral effect was noted in trial participants with the highest viral loads. Their cells demonstrated a statistically significant and up to a three-fold reduction in virus.

The results are important as they suggest that BIT225 has the potential to be included in future HIV elimination or cure strategies. It may provide a way to halt the ongoing cycle of infection and reinfection with virus from these long-lived cells. Targeting virus reservoirs is regarded as the 'holy grail' of current HIV research.

One important source of long-lived virus resides in the brain of HIV-infected patients, contributing to AIDS-related dementia. Up to 24% of people infected with HIV in Western populations develop some degree of neurological impairment. Monocyte lineage cells, known as microglia cells, are implicated in the condition. Additional data presented at the conference included the results of analyses of cerebrospinal fluid (CSF) from two of the trial participants receiving BIT225. The analyses showed that BIT225 is able to cross the blood-brain barrier, indicating that it may be a potential therapeutic option for treatment of this condition.

The BIT225 trial was conducted on 21 patients at an international clinical trial unit in Bangkok, Thailand. Patients enrolled in the study were HIV-infected, with high levels of virus and good CD4+ T cell counts. None had previously received treatment with anti-retroviral drugs. Patients received either BIT225 (400 mg; twice daily) or placebo for a period of 10 days.

Copies of the presentations are attached.

Enquiries

Dr Michelle Miller Rudi Michelson Managing Director Monsoon Communications Biotron Limited +61-3 9620 3333 +61-2 9805 0488 +61-(0)412313329 mmiller@biotron.com.au

About Biotron and BIT225

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

BIT225 is the first in a new class of antiviral drugs that may provide a new approach to the treatment of HIV. BIT225 is synergistic in vitro with commonly used anti-retroviral therapies and would potentially be used in conjunction with these treatments.

BIT225 is also in development for the treatment of Hepatitis C virus ('HCV') and has also recorded highly encouraging data in this indication. A phase 2a trial in HCV demonstrated that 100% of patients receiving BIT225 (400 mg) in combination with current standard of care therapies interferon and ribavirin had undetectable virus after 48 weeks.

A further phase 2 trial of BIT225 in patients co-infected with HIV and HCV is currently in progress.

Yours sincerely

==> picture [89 x 58] intentionally omitted <==

Peter J. Nightingale Company Secretary

pjn7282

2

==> picture [2551 x 3345] intentionally omitted <==

----- Start of picture text -----

BIT225, a Novel Inhibitor of HIV-1 Release
from HIV-1 Reservoirs of the Myeloid Lineage
John Wilkinson [1] , Carolyn Luscombe [1] , Gary Ewart [1] , Stephen Kerr [2] , Nattaya Tanliang [3] , Winai Ratanasuwan [3] , Robert Murphy [4] , and Michelle Miller [1]
1Biotron Limited, Sydney, Australia 2HIV-NAT, Bangkok, Thailand 3Siriraj Hospital, Bangkok, Thailand and 4Northwestern University, Chicago, IL, US
Introduction Results – Antiviral Efficacy & CSF Analysis Results – Baseline Characteristics & Safety
Viral reservoirs are a significant obstacle to eradication of HIV-1
Table 2. Baseline characteristics of the study
Figure 1. BIT225 therapy results in a reduction in virus
infection. Macrophages are an early target for HIV-1 infection
and serve as long term reservoirs of the virus. Therapeutic burden within the CD14 [+] monocytes. participants.
strategies aimed at fully eradicating HIV-1 from the host must The amount of virus within the CD14 [+] monocytes in the placebo The treated and placebo groups were well matched at baseline,
with no significant differences between the two groups in any of
also target these infected cells to be fully effective. group (n=7) remained constant throughout the study, with no
the parameters measured.
differences observed in the HIV-1 replication rate in the co-
The discovery that specific viral proteins have ion channel
cultures of cells collected from the 4 time points in the trial.
Total Placebo BIT225
activity (viroporins) led Biotron to design a library of >250
In the BIT225 treated arm (n=12), a reduced amount of virus was
compounds with >70% active against the Vpu target. BIT225 n 21 7 14
detected in the co-cultured cells from blood collected after 5 Female 10 3 7
was selected as the lead compound from this library. It days of drug treatment when compared to the day 0 bleed. This Male 11 4 7
Withdrew 2 0 2
demonstrates encouraging anti-HIV-1 activity in primary human
lower level of virus persisted out to the day 20 bleed, indicative
CD14 [+] monocyte-derived macrophages (MDMs). BIT225 Mean Age 29.2 27 30.4
of less HIV-1 present within the myeloid compartment in the
significantly reduces virus release from MDMs with an EC50 of drug-treated patients. HIV-1 VL (copies/mL)
1.1 ± 0.4 µM and a TC50 of 212 µM. Biotron has previously Median 27,199 20,521 27,997
Range 3,560 – 276,930 6,109 – 81,829 3,560 – 276,930
=
completed preclinical safety studies and a Phase 1 dose Placebo (n 7) BIT225 Treated (n=12) Log 4.43 4.29 4.45
16 16
Range 3.55 – 5.44 3.79 – 4.91 3.55 – 5.44
escalation study in healthy volunteers with BIT225 under its
14 14
HIV program. Day 0 Bleed CD4 Count (cells/mm3)
12 12
Day 5 Bleed Median 475 482 441
10 10 Day 10 Bleed Range 261 – 835 261 – 617 299 – 835
Here we report on the antiviral effects of BIT225 in the setting
Day 20 Bleed
8 8
of a recent Phase 1b/2a clinical trial conducted at the Siriraj
* Discontinued due to headache, nausea and vomiting (grade 1 & 2)
6 6
Hospital, Bangkok, Thailand in HIV-1 [+] individuals. Using a novel
4 4
co-culture assay measuring infectious virus from patient CD14 [+]
2 2
Table 3. A summary of the adverse events of the study
monocytes, we have demonstrated that treatment with BIT225
significantly reduced the level of HIV-1 within these cells. The participants.
5 10 15 20 25 5 10 15 20 25
results provide evidence that BIT225 can target and reduce the Time in Co-culture (days) Ten days of BIT225 treatment was well tolerated by the
viral burden in cells of the myeloid lineage in a clinical setting. participating HIV-1 [+] individuals. Headaches and nausea were the
most common adverse events and were the reason for
Figure 2. BIT225 therapy results in a significant
reduction in HIV-1 within the CD14 [+] monocytes of withdrawal or temporary discontinuation.
Aim patients with high viral loads.
Adverse Event BIT225 Placebo
When the 12 treated patients were split in to 2 groups,
The aim of this study was to utilise a novel endpoint-
Number of Events (%) (n=14) (n=7)
determined by the median viral load, those patients with high
analysis method with a drug designed to target the myeloid
Headache 12 (86) 2 (28)
viral loads (>4.43) demonstrated significantly less virus within the
cellular reservoirs of HIV-1, that exist in the presence (or Nausea 9 (64) 2 (28)
co-cultures of cells collected during BIT225 therapy.
absence) of active virus replication in T-cells. The new Vomiting 5 (36) 1 (14)
method examines the level of active HIV-1 infection in cells of Fever 5 (36) 0
High Viral Load (n=6) Low Viral Load (n=6)
16 16 Numbness/Parasthesia 5 (36) 0
the CD14 [+] monocyte lineage during 10 days of BIT225
treatment, by examining HIV-1 output from these cells e x vivo 14 14 Day 0 Bleed Dizziness 4 (29) 0
after isolation from BIT225-treated individuals. 12 12 Day 5 Bleed Rash 3 (21) 1 (14)
Day 10 Bleed Itchiness 3 (21) 0
10 10
Day 20 Bleed
In contrast to HIV-1 clinical trials using T cell-targeting drugs,
8 8
Two patients interrupted BIT225 for 2-4 days due to headache, dizziness,
the aim of this trial was not to measure a direct decrease in
6 6
nausea and vomiting One patient interrupted for 2 days due to palpitations
HIV-1 viral load, nor increase in CD4 [+] T-cell count; such an
4 4
effect would be unlikely for a short monotherapy trial of 2 2
Since completion of this trial, an optimised capsule formulation
BIT225, which targets HIV-1 replication in the macrophages.
of BIT225 has been developed and tested in healthy volunteers.
5 10 15 20 25 5 10 15 20 25
Time in Co-culture (days)
Mann-Whitney p=
0 v 5 0.25 0.09 0.1 0.05 0.04 0.2
0 v 10 0.25 0.31 0.31 0.42 0.44 0.28
0 v 20 0.25 0.28 0.31 0.37 0.35 0.54 Conclusion
Study Design
1.
A Phase 1b/2a, placebo-controlled, randomised study By measuring HIV-1 within the patients’ monocyte cells,
representing their myeloid population, we have shown that
of the safety, pharmacokinetics and antiviral activity
Figure 3. As expected, 10 days of BIT225 treatment had
BIT225 treatment significantly reduces the viral burden in
of BIT225 in patients with HIV-1 infection.
no effect upon patient (a) HIV-1 viral load and (b) CD4 [+] T
these cells Figures 1 and 2. The reduction was more evident
cell count.
Primary objective in those individuals with higher viral loads Figure 2.
Plotted are (i) absolute numbers and (ii) changes from baseline
The safety and tolerability of 400 mg of BIT225 BID compared
2.
As expected with a short duration single drug regimen
(day 0). There were no differences between the 14 treated (blue)
with placebo in patients with HIV-1 infection that were
targeting myeloid lineage cells, no changes in viral load or
versus 7 placebo (red) for either parameter measured.
antiretroviral therapy naïve.
the CD4 [+] T cell count were observed during the treatment
Secondary objectives period Figure 3.
(a) HIV-1 viral load (copies/mL)
•
The pharmacokinetics of 400 mg of BIT225 administered daily
3.
Analysis of CSF demonstrates that the drug is able to cross
(i) (ii)
on day 1 & 10 and twice daily on days 2 – 9.
the blood brain barrier Table 1.
•
The antiviral activity of BIT225.
4.
BIT225 has acceptable safety and tolerability in HIV-1 [+]
•
Evaluate BIT225 levels in cerebrospinal fluid (CSF) at day 10.
individuals Table 3.
Study design
Treatment with BIT225 demonstrated a significant
• A randomised, parallel, double-blind study of BIT225 in
effect upon the virus burden in the monocytes of those
patients with HIV-1 infection that are antiretroviral therapy
individuals with high viral loads. By targeting these
naïve. (b) CD4 [+] T cell counts (cells/mm [3] )
cells and preventing (re)seeding of the myeloid
• Open to males and females, aged 18 to 65 years, with HIV-1
(i) (ii)
infection (viral load >5,000 copies/mL; CD4+ count >350 reservoirs, BIT225 has a potential role in the
cells/mm [3] ) and that are antiretroviral therapy naïve. eradication strategy of HIV-1.
• 14 patients received 400 mg BIT225 and 7 received placebo.
Samples, CD14 [+] monocyte isolation and co-culture assay
Further information
For all patients, blood was collected on days 0, 5, 10 and 20 of
dosing. Plasma was stored and CD14 [+] monocytes isolated from Contact: j.wilkinson@amr.org.au ( Senior Virologist )
the 21 study participants by magnetic bead sorting at each of mmiller@biotron.com.au ( CEO & Managing Director )
Table 1. Concentration of BIT225 in the CSF.
and CD14 [-]
these 4 time points. In addition, CD14 [+] (T cell)
Samples of CSF were collected from two subjects at 4 hours post- Or visit: www.biotron.com.au
samples were stored for single copy HIV-1 RNA & DNA assays.
dosing on day 10. Drug was detectable in the CSF, albeit at lower
levels than those seen in plasma.
At each of the 4 time points, the isolated CD14 [+] monocytes Acknowledgements
were combined with MT4 T cells and co-cultured ex vivo for 25 We would especially like to thank the trial participants for their involvement
Subject CSF (ng/ml) Plasma (ng/ml)
in this study. In addition, a big thank you to the staff at ACLIRES and the
days. HIV-1 replication in the co-culture was determined by
402 87.8 3550 Department of Medicine at Siriraj Hospital for their assistance with this trial
p24 ELISA of the co-culture supernatant after 5, 10, 15, 20 and
418 24.4 1620 and making us feel very welcome throughout our stay in Bangkok.
25 of culture.
(Lower limit of quantitation of HPLC assay for BIT225 in CSF is 0.200 ng/ml)
HIV-1 Replication (pg/200uL)
HIV-1 Replication (pg/200uL)
HIV-1 (copies/mL)
# (cells/mm3)
+
CD4
----- End of picture text -----

==> picture [2551 x 9] intentionally omitted <==

==> picture [2551 x 21] intentionally omitted <==

==> picture [144 x 38] intentionally omitted <==

==> picture [171 x 72] intentionally omitted <==

**BIT225,

a
Novel
Inhibitor
of
HIV-­‐1
Release
from
HIV-­‐1 Reservoirs
of
the
Myeloid
Lineage**

-­‐
John
Wilkinson
-­‐ Biotron
Limited,
Australia

==> picture [720 x 87] intentionally omitted <==

IAS 2013 Towards an HIV Cure Symposium

==> picture [174 x 73] intentionally omitted <==

BIT225 (N-­‐[5-­‐(1-­‐Methyl-­‐1H-­‐pyrazol-­‐4-­‐yl)-­‐napthalene-­‐2-­‐
carbonyl]-­‐guanidine)

==> picture [151 x 64] intentionally omitted <==

• First-­‐in-­‐class
  drug
  targeHng
  HIV-­‐1
  within
  cells
  of
  the
  myeloid
  lineage
  (selected

• as
  lead
  from
  ~250
  compound
  library
  designed
  to
  target
  Vpu)

• AnH-­‐HIV-­‐1
  acHvity
  in
  primary
  human
  CD14[+] MDM
  assay:

• >90%
  inhibi*on
  of
  HIV-­‐1
  release
  (RT
  &
  p24)

• IC50
  of
  ~1.1
  ±
  0.4
  uM
  TC50
  of
  212
  uM

• Also
  acHve
  in
  DCs

==> picture [141 x 96] intentionally omitted <==

----- Start of picture text -----

O NH
N NH2
H
H3C N N

BIT225
----- End of picture text -----

• Targets
  Vpu
  ion
  channels,
  with
  no
  effect
  on
  HIV-­‐2

• No
  effect
  on
  reverse
  transcripHon
  or
  on
  the
  RTase
  or
  protease
  enzymes

• Acts
  post-­‐integraHon

A B Visualisa7on
by
EM
of
(A)
DMSO
(B)
BIT225 treated
cells

• EM
  suggests
  defects
  in
  virion
  packaging/budding

• Good
  safety
  and
  PK
  profiles
  in
  preclinical

• toxicology
  studies
  and
  Phase
  1
  human
  trials

==> picture [720 x 47] intentionally omitted <==

Significant

HIV-­‐1
ReducHon
in
Human Macrophages in
vitro with
BIT225

==> picture [151 x 64] intentionally omitted <==

==> picture [435 x 292] intentionally omitted <==

----- Start of picture text -----

Chronic Kinetics
d14 infection & d21 BIT225 addition
200
150
100 +BIT225
50
16 17 19 21 22 23 24 25 26 27 28
Time (days)
+HIV-1
HIV-1 Replication RT
----- End of picture text -----

==> picture [75 x 44] intentionally omitted <==

----- Start of picture text -----

DMSO
Control
BIT225
----- End of picture text -----

Khoury
et
al., An7microbial
Agents
and
Chemotherapy.
2009

==> picture [720 x 47] intentionally omitted <==

Monocytes

and
HIV-­‐1
InfecHon

==> picture [151 x 64] intentionally omitted <==

• CD14[+] monocytes
(~30%)
are
long
lived
cells
with
reports
that
once
infected they
can
disseminate
virus
for
6
weeks in
vitro (Sharova et
al EMBO
J
2005) • The
minor
CD16[+] subset
(5-­‐10%
of
monocytes)
are
preferenHally
infected; higher
CCR5
levels
(Ellery et
al JI
2007)

• Circulate
  in
  the
  blood
  for
  ~1
  day
  before
  entering
  the
  Hssue
  -­‐>
  MØ

• Important
  wrt
  transmission
  and
  seeding
  the
  Hssues
  (brain)

• HIV-­‐1
can
be
isolated
from
monocytes
(Wang et
al Plos
One
2013),
their
HPC precursors
(Carter et
al Nat
Med
2010)
and
thought
to
contribute
to
viral persistence
(Le
Douce et
al Retrovirology
2010)

• Treatment
regimens
fail
to
inhibit
HIV-­‐1
DNA
persistence
in
monocytes
(Sonza et
al AIDS
2001;
Zhu et
al JV
2002;
Llewellyn et
al JLB
2006)
but
they
are
not
a
major reservoir
in
elite
suppressors
(Spivak et
al JV
2011)

==> picture [720 x 47] intentionally omitted <==

BIT225 A

Phase
1b/2a
Trial
with

==> picture [151 x 64] intentionally omitted <==

BIT225-­‐004,
a
Phase
1b/2a,
Placebo-­‐Controlled,
Randomised Study
of
the
Safety,
Pharmacokine7cs
and
An7viral
Ac7vity
of BIT225
in
Pa7ents
with
Human
Immunodeficiency
Virus-­‐1 Infec7on Robert
Murphy,
Winai
Ratanasuwan and
Ruengpung
SuIhent ACLIRES
and
Dept
of
Medicine, Siriraj
Hospital,
Bangkok,
Thailand

==> picture [720 x 47] intentionally omitted <==

BIT225-­‐004:

Synopsis

==> picture [151 x 64] intentionally omitted <==

_**Primary

objec7ve**_

The
safety
and
tolerability
of
400
mg
of
BIT225
BID
compared
with
placebo
in
paHents with
HIV-­‐1
infecHon
that
are
anHretroviral
therapy
naïve

_**Secondary

objec7ves**_

• The
  pharmacokineHcs
  of
  400
  mg
  of
  BIT225
  administered
  daily
  on
  day
  1
  &
  10
  and

• twice
  daily
  on
  days
  2
  -­‐
  9

• The anHviral acHvity of BIT225

• Evaluate
  BIT225
  levels
  in
  cerebrospinal
  fluid
  at
  day
  10
  (opHonal
  day
  9)

Study
design

• A
  randomized,
  parallel,
  double-­‐blind
  study
  of
  BIT225
  in
  paHents
  with
  HIV-­‐1
  infecHon

• that
  are
  anHretroviral
  therapy
  naïve

• Males
  and
  females,
  aged
  18
  to
  65
  years,
  with
  HIV-­‐1
  infecHon
  (viral
  load

  5,000

• copies/mL;
  CD4+
  count

  350
  cells/mm[3] )
  and
  that
  are
  anHretroviral
  therapy
  naïve • 14
  paHents
  receiving
  400
  mg
  BIT225
  and
  7
  receiving
  placebo

==> picture [720 x 47] intentionally omitted <==

BIT225

AnHviral
AcHvity
in
a
Clinical
Sepng

==> picture [151 x 64] intentionally omitted <==

In
a
study
of
only
10
days
with
a
drug
targeHng
cells
of
the
myeloid
lineage, dramaHc
decreases
in
HIV-­‐1
viral
load
and
concomitant
increases
in
CD4[+] T
cell number
are
unlikely
to
be
observed.
Issues
with
access
to
macrophages Aim: To
determine
the
effect
of
BIT225
on
the
viral
burden
in
circulaHng CD14[+] monocytes
in
HIV-­‐1[+
] individuals CD14[+] Method: monocytes
were
isolated
with
magneHc
beads
on
days
0,
5,
10 and
20
and
co-­‐cultured
with
MT4
HIV-­‐1[-­‐] T
cells
for
25
days

==> picture [278 x 167] intentionally omitted <==

Time
in
coculture
(days)

Monocytes
isolated
Day
0
–
No
drug Monocytes
isolated
day
5
of
225
Rx Monocytes
isolated
day
10
of
225
Rx

==> picture [720 x 47] intentionally omitted <==

Monocyte

Co-­‐Culture
Assay

==> picture [151 x 64] intentionally omitted <==

==> picture [663 x 318] intentionally omitted <==

----- Start of picture text -----

Placebo
(n=7) BIT225
Treated
(n=12)
16 16
Day
0
Bleed
14 14 Day
5
Bleed
12 12 Day
10
Bleed
Day
20
Bleed
10 10
8 8
6 6
4 4
2 2
5 10 15 20 25 5 10 15 20 25
Time
in
Co-­‐culture
(days)
----- End of picture text -----

==> picture [720 x 47] intentionally omitted <==

Monocyte

Co-­‐Culture
Assay BIT225
Treated:
High
Viral
Load
n=6

==> picture [151 x 64] intentionally omitted <==

==> picture [475 x 280] intentionally omitted <==

----- Start of picture text -----

16
14 Day
0
Bleed
Day
5
Bleed
12 Day
10
Bleed
Day
20
Bleed
10
8
6
4
2
5 10 15 20 25
Time
in
Co-­‐culture
(days)
HIV-­‐1
ReplicaHon
(pg/200uL)
----- End of picture text -----

Mann-­‐Whitney
p= 0
v
5 0.25

0.09

0.1 **0.05

0.04 0.2 0
v
10** 0.25

0.31

0.31

0.42

0.44

0.28 0
v
20 0.25

0.28

0.31

0.37

0.35

0.54

==> picture [720 x 47] intentionally omitted <==

Monocyte

Co-­‐Culture
Assay BIT225
Treated:
Low
Viral
Load
n=6

==> picture [151 x 64] intentionally omitted <==

==> picture [514 x 282] intentionally omitted <==

----- Start of picture text -----

16
14
12
Day
0
Bleed
10
Day
5
Bleed
Day
10
Bleed
8 Day
20
Bleed
6
4
2
5 10 15 20 25
Time in co-culture (days)
HIV-­‐1
ReplicaHon
(pg/200uL)
----- End of picture text -----

==> picture [720 x 47] intentionally omitted <==

In

Summary

==> picture [151 x 64] intentionally omitted <==

• This
study
strengthens
our
previous
findings in
vitro and ex
vivo , supporHng
the
role
for
BIT225
as
a
novel
drug
targeHng
HIV-­‐1
within
the myeloid
compartment

• In
those
paHents
with
high
HIV-­‐1[+] viral
loads,
treatment
with
BIT225
for
10 days
significantly
reduced
the
amount
of
infecHous
HIV-­‐1
within
the circulaHng
CD14[+] monocyte
populaHon

• Single
Copy
HIV-­‐1
RT-­‐PCR
Analysis:
For
21
paHents
at
the
4
bleeds,
RNA
and
DNA (in
triplicate)
has
been
isolated
and
stored
for
HIV
RNA
and
HIV
DNA
analysis • By
targeHng
these
cells
and
prevenHng
the
(re)seeding
of
the
reservoirs, is
there
a
potenHal
role
for
BIT225
in
the
eradicaHon
strategy?

==> picture [720 x 47] intentionally omitted <==

Acknowledgements

==> picture [151 x 64] intentionally omitted <==

Biotron
Limited Dr
Michelle
Miller Dr
Carolyn
Luscombe Dr
Gary
Ewart Audrey
Thomson Bronwyn
Williams Craig
Witherington Gabriela
Khoury

ACLIRES Prof
Rob
Murphy Dr
Sven-­‐Iver
Lorenzen Siriraj
Hospital Trial
ParHcipants A/Prof
Winai
Ratanasuwan Prof
Ruengpung
Suuhent Nauaya
Tanliang

Melbourne
University Dr
Simon
Crawford

HIVNAT Dr
Stephen
Kerr

Poster: MOLBPE11

==> picture [720 x 47] intentionally omitted <==